Sweden
Key Insights
- 1
No psychedelic therapy is approved for routine care in Sweden; psilocybin remains narcotic-classified and usable only in tightly controlled research, while esketamine is available only as a regulated medicine for depression.
- 2
Sweden counts 8 psychedelic trials, 1 active, and 9 research organisations; psilocybin dominates the active portfolio, ahead of ketamine, esketamine and placebo.
- 3
Lund University’s 2025 anorexia pilot is the first global systematic psilocybin study in young anorexia patients, with 40 participants aged 16-35.
- 4
Momentum is now concentrated at Karolinska Institutet and Uppsala University: KI’s PSIPET is a Sweden-first phase II psilocybin depression trial, and Uppsala secured €6.5 million for PsyPal.
Reimbursed Care Access
Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the subject of Swedish health-economics assessment; access is limited to specialist psychiatry with supervised administration and regional/clinic-level funding decisions. Ketamine is an authorised anaesthetic and used in Swedish clinical research and some specialised/privately delivered off‑label psychiatric protocols, but routine outpatient ketamine infusion therapy for psychiatric indications is not a standard, nationally reimbursed service.
Quick Indicators
Organizations
1229k International AB
Sweden
CTC Clinical Trial Consultants AB
Sweden
European Commission (Horizon Europe)
European Medicines Agency (EMA)
European Union Drugs Agency (EUDA)
HumanKindLabs
Sweden
Karolinska Institutet
Sweden
Norrsken Mind
Sweden
PSIPET Research Group
Karolinska Institute
Region Örebro County
Sweden
Stockholm University
Sweden
Vastra Gotaland Region
Research Events
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Sweden.